SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Farrell RJ, Kelly CP 2002 Celiac sprue. N Engl J Med 346: 180188.
  • 2
    Collin P, Kaukinen K, Valimaki M, Salmi J 2002 Endocrinological disorders and celiac disease. Endocr Rev 23: 464483.
  • 3
    Kemppainen T, Kroger H, Janatuinen E, Arnala I, Kosma VM, Pikkarainen P, Julkunen R, Jurvelin J, Alhava E, Uusitupa M 1999 Osteoporosis in adult patients with celiac disease. Bone 24: 249255.
  • 4
    Bianchi ML, Bardella MT 2002 Bone and celiac disease. Calcif Tissue Int 71: 465471.
  • 5
    Harada S, Rodan GA 2003 Control of osteoblast function and regulation of bone mass. Nature 423: 349355.
  • 6
    Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289: 15041508.
  • 7
    Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423: 337342.
  • 8
    Ducy P, Schinke T, Karsenty G 2000 The osteoblast: A sophisticated fibroblast under central surveillance. Science 289: 15011504.
  • 9
    Southerland JC, Valentine JF 2001 Osteopenia and osteoporosis in gastrointestinal diseases: Diagnosis and treatment. Curr Gastroenterol Rep 3: 399407.
  • 10
    Selby PL, Davies M, Adams JE, Mawer EB 1999 Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 4: 652657.
  • 11
    Raisz LG 1999 Physiology and pathophysiology of bone remodeling. Clin Chem 45: 13531358.
  • 12
    Goldring SR 2003 Mechanisms of pathologic bone loss. Calcif Tissue Int 73: 97100.
  • 13
    Kontakou M, Przemioslo RT, Sturgess RP, Limb AC, Ciclitira PJ 1996 Expression of tumor necrosis factor-alpha, interleukin-6 and inteleukin-2 mRNA in the jejunum of patients with coeliac disease. Scand J Gastroenterol 30: 456463.
  • 14
    Fornari MC, Pedreira S, Niveloni S, Gonzalez D, Diez RA, Vazquez H, Mazure R, Sugai E, Smecuol E, Boerr L, Maurino E, Bai JC 1998 Pre- and post-treatment serum levels of cytokines IL-1beta, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? Am J Gastroenterol 93: 413418.
  • 15
    Salvati VM, MacDonald TT, Bajaj-Elliott M, Borrelli M, Staiano A, Auricchio S, Troncone R, Monteleone G 2002 Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 50: 186190.
  • 16
    Caselli GF, Mantovanini M, Gandolfi CA, Allegretti M, Fiorentino S, Pellegrini L, Melillo G, Bestini R, Sabbatici W, Anacardio R, Clavenna G, Sciortino G, Teti A 1997 Tartronates: A new generation of drugs affecting bone metabolism. J Bone Miner Res 12: 972981.
  • 17
    Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF, Baron R, Teti A 2000 Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151: 311320.
  • 18
    Chomczynski P, Sacchi N 1987 Single step method of RNA isolated by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann Biochem 162: 156159.
  • 19
    Karsenty G 2003 The complexity of skeletal biology. Nature 423: 316318.
  • 20
    Martin RB 2003 Fatigue microdamage as an essential element of bone mechanics and biology. Calcif Tissue Int 73: 101107.
  • 21
    Goldring SR, Gravallese EM 2000 Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12: 195199.
  • 22
    Goldring SR 2002 Bone and joint destruction in rheumatoid arthritis: What is really happening? J Rheumatol Suppl 65: 4448.
  • 23
    Firestein GS 2003 Evolving concepts of rheumatoid arthritis. Nature 423: 356361.
  • 24
    Rodan GA, Martin TJ 2000 Therapeutic approaches to bone diseases. Science 289: 15081514.
  • 25
    Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT 2001 Osteolysis: Basic science. Clin Orthop 393: 7177.
  • 26
    Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM 2003 Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111: 821831.
  • 27
    Buckley KA, Fraser WD 2002 Receptor activator for nuclear factor kappa B and osteoprotegerin: Regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Ann Clin Biochem 39: 551556.
  • 28
    Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, Kinosaki M, Yamaguchi K, Tsuda E, Murakami A, Yasuda H, Higashio K 2002 Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 20: 337344.
  • 29
    Nagata N, Kitaura H, Yoshida N, Nakayama K 2003 Inhibition of RANKL-induced osteoclast formation in mouse marrow cells by IL-12: Involvement of IFN-gamma possibly induced from non-T cell population. Bone 33: 721732.
  • 30
    Miossee P 2001 Cytokines in rheumatoid arthritis: Is it all TNF-alpha? Cell Mol Biol 47: 675678.
  • 31
    Boneberg EM, Hartung T 2002 Molecular aspects of anti-inflammatory action of G-CSF. Inflamm Res 51: 119128.
  • 32
    Horwood NJ, Elliott J, Martin TJ, Gillespie MT 2001 IL-12 alone and in synergy with Il-18 inhibits osteoclast formation in vitro. J Immunol 15: 49154921.
  • 33
    Yamada N, Niwa S, Tsujimura T, Iwasaki T, Sugihara A, Futani H, Hayashi S, Okamura H, Akedo H, Terada N 2002 Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone 30: 901908.
  • 34
    Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, Kurimoto M, Dunn AR, Martin TJ, Gillespie MT 1998 Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 101: 595603.
  • 35
    Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB 1999 A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104: 13931401.
  • 36
    Watrous DA, Andrews BS 1989 The metabolism and immunology of bone. Semin Arthritis Rheum 19: 4565.
  • 37
    Hayashi T, Kaneda T, Toyama Y, Kumegawa M, Hakeda Y 2002 Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J Biol Chem 277: 2788027886.